US 10,376,525 B2
Treprostinil administration by inhalation
Horst Olschewski, Graz (AT); Robert Roscigno, Chapel Hill, NC (US); Lewis J. Rubin, LaJolla, CA (US); Thomas Schmehl, Giessen (DE); Werner Seeger, Giessen (DE); Carl Sterritt, Weybridge (GB); and Robert Voswinckel, Giessen (DE)
Assigned to United Therapeutics Corporation, Silver Spring, MD (US)
Filed by United Therapeutics Corporation, Silver Spring, MD (US)
Filed on Feb. 1, 2016, as Appl. No. 15/11,999.
Application 15/011,999 is a division of application No. 13/469,854, filed on May 11, 2012, granted, now 9,339,507.
Application 13/469,854 is a division of application No. 12/591,200, filed on Nov. 12, 2009, granted, now 9,358,240.
Application 12/591,200 is a continuation of application No. 11/748,205, filed on May 14, 2007, abandoned.
Claims priority of provisional application 60/800,016, filed on May 15, 2006.
Prior Publication US 2016/0143868 A1, May 26, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/192 (2006.01); A61P 9/12 (2006.01); A61M 11/00 (2006.01); A61K 31/557 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/557 (2013.01) [A61K 9/008 (2013.01); A61K 9/0078 (2013.01); A61K 31/192 (2013.01)] 4 Claims
 
1. A method of treating pulmonary hypertension comprising: administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising from 200 to 1000 μg/ml of treprostinil or a pharmaceutically acceptable salt thereof with a pulsed ultrasonic nebulizer that aerosolizes a fixed amount of treprostinil or a pharmaceutically acceptable salt thereof per pulse, said pulsed ultrasonic nebulizer comprising an opto-acoustical trigger that allows said human to synchronize each breath to each pulse, said therapeutically effective single event dose comprising from 15 μg to 90 μg of treprostinil or a pharmaceutically acceptable salt thereof delivered in 3 to 18 breaths, wherein the fixed amount of treprostinil or its pharmaceutically acceptable salt for each breath inhaled by the human comprises at least 5 μg of treprostinil or its pharmaceutically acceptable salt.